The Liver-Heart Axis. A Bidirectional Relationship?
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world with a prevalence of 20–30% in the general population and 50–90% in populations with obesity and type 2 diabetes mellitus (T2DM). It it commonly leads to cardiovascular disease (CVD) due to a dysmetabolic and inflammatory milieu of impaired glucose tolerance, dyslipidaemia, and high blood pressure. Irrespective of their connection, it is clear that when treating patients with NAFLD, CVD must be addressed and vice versa.
Recognising Oestrogen’s Role in Cardiometabolic Disease
Almost half of women in their 50s and nearly three-quarters of women in their 70s have hypertension and it is viewed as the overall burden of disease to women. Despite this, women are traditionally thought to be at less risk of cardiovascular disease (CVD), and as such experience less screening compared to men. Considering that blood pressure is a marker of endothelial function, which is influenced by insulin resistance, oxidative stress and/or inflammation, the question is always what is impacting the endothelial health?
Artemisia species in listed medicines notice
In October this year, the Therapeutic Goods Administration (TGA) issued a safety alert on listed medicines containing Artemisia species and the potential risk of embryotoxicity during pregnancy. This followed with a notification by the TGA on the 14th December, requesting an immediate cease of supply of all listed medicines containing Artemisia annua, Artemisia absinthium and/or artemisinin that do not list a pregnancy warning on the product label. Due to this announcement, Integria Healthcare, the owner of the MediHerb® brand has temporarily ceased supply of formulated products that contain Artemisia species.